Desmopressin  ||| S:0 E:13 ||| JJ
testing  ||| S:13 E:21 ||| NN
in  ||| S:21 E:24 ||| IN
children  ||| S:24 E:33 ||| NNS
with  ||| S:33 E:38 ||| IN
von  ||| S:38 E:42 ||| NNP
Willebrand  ||| S:42 E:53 ||| NNP
syndrome  ||| S:53 E:62 ||| NN
in  ||| S:62 E:65 ||| IN
haemostaseologic  ||| S:65 E:82 ||| JJ
centers  ||| S:82 E:90 ||| NNS
of  ||| S:90 E:93 ||| IN
Saxonia ||| S:93 E:100 ||| NNP
,  ||| S:100 E:102 ||| ,
Saxonia-Anhalt  ||| S:102 E:117 ||| JJ
and  ||| S:117 E:121 ||| CC
Thuringia  ||| S:121 E:131 ||| NNP
The  ||| S:131 E:135 ||| DT
influence  ||| S:135 E:145 ||| NN
of  ||| S:145 E:148 ||| IN
desmopressin  ||| S:148 E:161 ||| NN
on  ||| S:161 E:164 ||| IN
hemostasis  ||| S:164 E:175 ||| NN
is  ||| S:175 E:178 ||| VBZ
mediated  ||| S:178 E:187 ||| VBN
by  ||| S:187 E:190 ||| IN
the  ||| S:190 E:194 ||| DT
release  ||| S:194 E:202 ||| NN
of  ||| S:202 E:205 ||| IN
von  ||| S:205 E:209 ||| NNP
Willebrand  ||| S:209 E:220 ||| NNP
factor  ||| S:220 E:227 ||| NN
and  ||| S:227 E:231 ||| CC
of  ||| S:231 E:234 ||| IN
coagulation  ||| S:234 E:246 ||| JJ
factor  ||| S:246 E:253 ||| NN
VIII  ||| S:253 E:258 ||| NN
from  ||| S:258 E:263 ||| IN
vascular  ||| S:263 E:272 ||| JJ
endothelium ||| S:272 E:283 ||| NN
.  ||| S:283 E:285 ||| .
The  ||| S:285 E:289 ||| DT
necessity  ||| S:289 E:299 ||| NN
of  ||| S:299 E:302 ||| IN
testing  ||| S:302 E:310 ||| VBG
desmopressin  ||| S:310 E:323 ||| JJ
effectiveness  ||| S:323 E:337 ||| NN
on  ||| S:337 E:340 ||| IN
hemostasis  ||| S:340 E:351 ||| NN
is  ||| S:351 E:354 ||| VBZ
a  ||| S:354 E:356 ||| DT
matter  ||| S:356 E:363 ||| NN
of  ||| S:363 E:366 ||| IN
controversy  ||| S:366 E:378 ||| NN
and  ||| S:378 E:382 ||| CC
the  ||| S:382 E:386 ||| DT
performance  ||| S:386 E:398 ||| NN
of  ||| S:398 E:401 ||| IN
the  ||| S:401 E:405 ||| DT
test  ||| S:405 E:410 ||| NN
is  ||| S:410 E:413 ||| VBZ
not  ||| S:413 E:417 ||| RB
yet  ||| S:417 E:421 ||| RB
standardized ||| S:421 E:433 ||| JJ
.  ||| S:433 E:435 ||| .
For  ||| S:435 E:439 ||| IN
this  ||| S:439 E:444 ||| DT
reason  ||| S:444 E:451 ||| NN
the  ||| S:451 E:455 ||| DT
desmopressin  ||| S:455 E:468 ||| JJ
tests  ||| S:468 E:474 ||| NNS
in  ||| S:474 E:477 ||| IN
114  ||| S:477 E:481 ||| CD
children  ||| S:481 E:490 ||| NNS
with  ||| S:490 E:495 ||| IN
von  ||| S:495 E:499 ||| NNP
Willebrand  ||| S:499 E:510 ||| NNP
syndrome  ||| S:510 E:519 ||| NN
( ||| S:519 E:520 ||| -LRB-
type  ||| S:520 E:525 ||| NN
1 ||| S:525 E:526 ||| CD
,  ||| S:526 E:528 ||| ,
n=98 ||| S:528 E:532 ||| NNP
;  ||| S:532 E:534 ||| :
type  ||| S:534 E:539 ||| CD
2A ||| S:539 E:541 ||| CD
,  ||| S:541 E:543 ||| ,
n=12 ||| S:543 E:547 ||| NNP
;  ||| S:547 E:549 ||| :
type  ||| S:549 E:554 ||| CD
2M ||| S:554 E:556 ||| CD
,  ||| S:556 E:558 ||| ,
n=2 ||| S:558 E:561 ||| NNP
;  ||| S:561 E:563 ||| :
type  ||| S:563 E:568 ||| CD
2N ||| S:568 E:570 ||| CD
,  ||| S:570 E:572 ||| ,
n=2 ||| S:572 E:575 ||| CD
)  ||| S:575 E:577 ||| -RRB-
carried  ||| S:577 E:585 ||| VBD
out  ||| S:585 E:589 ||| RP
in  ||| S:589 E:592 ||| IN
7  ||| S:592 E:594 ||| CD
paediatric  ||| S:594 E:605 ||| CD
haemostaseologic  ||| S:605 E:622 ||| CD
centers  ||| S:622 E:630 ||| NNS
were  ||| S:630 E:635 ||| VBD
retrospectively  ||| S:635 E:651 ||| JJ
analyzed ||| S:651 E:659 ||| NN
.  ||| S:659 E:661 ||| .
The  ||| S:661 E:665 ||| DT
effectiveness  ||| S:665 E:679 ||| NN
of  ||| S:679 E:682 ||| IN
desmopressin  ||| S:682 E:695 ||| NN
was  ||| S:695 E:699 ||| VBD
assessed  ||| S:699 E:708 ||| VBN
using  ||| S:708 E:714 ||| VBG
defined  ||| S:714 E:722 ||| VBN
response  ||| S:722 E:731 ||| NN
criteria ||| S:731 E:739 ||| NNS
.  ||| S:739 E:741 ||| .
As  ||| S:741 E:744 ||| RB
expected ||| S:744 E:752 ||| VBN
,  ||| S:752 E:754 ||| ,
the  ||| S:754 E:758 ||| DT
test  ||| S:758 E:763 ||| NN
performance  ||| S:763 E:775 ||| NN
showed  ||| S:775 E:782 ||| VBD
a  ||| S:782 E:784 ||| DT
wide  ||| S:784 E:789 ||| JJ
variation  ||| S:789 E:799 ||| NN
among  ||| S:799 E:805 ||| IN
the  ||| S:805 E:809 ||| DT
centers ||| S:809 E:816 ||| NNS
.  ||| S:816 E:818 ||| .
In  ||| S:818 E:821 ||| IN
99  ||| S:821 E:824 ||| CD
children  ||| S:824 E:833 ||| NNS
desmopressin  ||| S:833 E:846 ||| NN
was  ||| S:846 E:850 ||| VBD
given  ||| S:850 E:856 ||| VBN
intravenously  ||| S:856 E:870 ||| VBN
as  ||| S:870 E:873 ||| IN
a  ||| S:873 E:875 ||| DT
short  ||| S:875 E:881 ||| JJ
infusion  ||| S:881 E:890 ||| NN
at  ||| S:890 E:893 ||| IN
a  ||| S:893 E:895 ||| DT
dosage  ||| S:895 E:902 ||| NN
ranging  ||| S:902 E:910 ||| VBG
from  ||| S:910 E:915 ||| IN
0.25  ||| S:915 E:920 ||| CD
to  ||| S:920 E:923 ||| TO
0.41  ||| S:923 E:928 ||| CD
microg ||| S:928 E:934 ||| CD
/ ||| S:934 E:935 ||| CD
kg  ||| S:935 E:938 ||| NNS
and  ||| S:938 E:942 ||| CC
in  ||| S:942 E:945 ||| IN
15  ||| S:945 E:948 ||| CD
intranasally  ||| S:948 E:961 ||| NN
at  ||| S:961 E:964 ||| IN
an  ||| S:964 E:967 ||| DT
absolute  ||| S:967 E:976 ||| JJ
dose  ||| S:976 E:981 ||| NN
of  ||| S:981 E:984 ||| IN
40  ||| S:984 E:987 ||| CD
to  ||| S:987 E:990 ||| TO
300  ||| S:990 E:994 ||| CD
microg ||| S:994 E:1000 ||| NNS
.  ||| S:1000 E:1002 ||| .
The  ||| S:1002 E:1006 ||| DT
points  ||| S:1006 E:1013 ||| NNS
of  ||| S:1013 E:1016 ||| IN
time  ||| S:1016 E:1021 ||| NN
for  ||| S:1021 E:1025 ||| IN
blood  ||| S:1025 E:1031 ||| NN
taking  ||| S:1031 E:1038 ||| VBG
after  ||| S:1038 E:1044 ||| IN
desmopressin  ||| S:1044 E:1057 ||| JJ
application  ||| S:1057 E:1069 ||| NN
ranged  ||| S:1069 E:1076 ||| VBD
from  ||| S:1076 E:1081 ||| IN
0.5  ||| S:1081 E:1085 ||| CD
to  ||| S:1085 E:1088 ||| TO
12  ||| S:1088 E:1091 ||| CD
h ||| S:1091 E:1092 ||| NNS
.  ||| S:1092 E:1094 ||| .
The  ||| S:1094 E:1098 ||| DT
absent  ||| S:1098 E:1105 ||| JJ
desmopressin  ||| S:1105 E:1118 ||| JJ
response  ||| S:1118 E:1127 ||| NN
in  ||| S:1127 E:1130 ||| IN
7  ||| S:1130 E:1132 ||| CD
patients  ||| S:1132 E:1141 ||| NNS
( ||| S:1141 E:1142 ||| -LRB-
6 ||| S:1142 E:1143 ||| CD
% ||| S:1143 E:1144 ||| NN
)  ||| S:1144 E:1146 ||| -RRB-
and  ||| S:1146 E:1150 ||| CC
the  ||| S:1150 E:1154 ||| DT
partial  ||| S:1154 E:1162 ||| JJ
response  ||| S:1162 E:1171 ||| NN
in  ||| S:1171 E:1174 ||| IN
15  ||| S:1174 E:1177 ||| CD
indicate  ||| S:1177 E:1186 ||| VBP
the  ||| S:1186 E:1190 ||| DT
necessity  ||| S:1190 E:1200 ||| NN
of  ||| S:1200 E:1203 ||| IN
testing  ||| S:1203 E:1211 ||| VBG
desmopressin  ||| S:1211 E:1224 ||| JJ
effectiveness  ||| S:1224 E:1238 ||| NN
before  ||| S:1238 E:1245 ||| IN
the  ||| S:1245 E:1249 ||| DT
first  ||| S:1249 E:1255 ||| JJ
therapeutic  ||| S:1255 E:1267 ||| JJ
use ||| S:1267 E:1270 ||| NN
.  ||| S:1270 E:1272 ||| .
The  ||| S:1272 E:1276 ||| DT
application  ||| S:1276 E:1288 ||| NN
of  ||| S:1288 E:1291 ||| IN
desmopressin  ||| S:1291 E:1304 ||| NN
was  ||| S:1304 E:1308 ||| VBD
well  ||| S:1308 E:1313 ||| RB
tolerated  ||| S:1313 E:1323 ||| VBN
by  ||| S:1323 E:1326 ||| IN
the  ||| S:1326 E:1330 ||| DT
patients ||| S:1330 E:1338 ||| NNS
.  ||| S:1338 E:1340 ||| .
